Last updated: March 2026
Fasoracetam stands apart from other racetams by upregulating GABA-B receptors rather than primarily enhancing choline uptake. It completed Phase 2 clinical trials in adolescents with ADHD carrying metabotropic glutamate receptor (mGluR) gene variants, and is used to reverse phenibut and baclofen tolerance.
Fasoracetam's pharmacology is distinct from most other racetams. While piracetam and oxiracetam focus on AMPA/NMDA glutamate modulation and HACU, fasoracetam's primary characterized effect is upregulation of GABA-B receptors and modulation of metabotropic glutamate receptors (mGluR1 and mGluR5). This makes it uniquely relevant for GABA-dependent conditions.
Fasoracetam upregulates GABA-B receptors in the brain — increasing both receptor expression and sensitivity. GABA-B receptors are the targets of baclofen and phenibut. Chronic use of those substances causes receptor downregulation (tolerance). Fasoracetam reverses this process, restoring receptor density and re-sensitizing the GABA-B system. This is its most unique and clinically relevant mechanism.
Fasoracetam modulates metabotropic glutamate receptors (mGluR1 and mGluR5). In the NFC-1 trial, adolescents selected for ADHD specifically needed to carry mutations in mGluR-related genes (CNTN4, CNTNAP2, GRM7 and others). This suggests fasoracetam's ADHD benefit is specifically mediated via mGluR pathways — not necessarily applicable to all ADHD subtypes.
Like other racetams, fasoracetam also enhances high-affinity choline uptake (HACU) in cortical and hippocampal neurons, increasing acetylcholine availability. This is a secondary mechanism compared to its GABA-B effects but contributes to its cognitive profile. As with other racetams, choline supplementation may reduce headache risk and improve effects.
Fasoracetam is typically administered sublingually at 20-100mg doses. Sublingual absorption bypasses first-pass hepatic metabolism, producing faster onset (~15-30 minutes) compared to oral administration. The compound is held under the tongue for 1-2 minutes. Some users also dissolve powder in water for oral use, though bioavailability may differ between routes.
Fasoracetam has more clinical trial data than most nootropic racetams, thanks to its development as NFC-1 by NeuroFix. The ADHD trials specifically targeted adolescents with mGluR gene mutations — an important patient-selection caveat.
Fasoracetam is best taken sublingually. Consider a micro-scale for accurate low-dose measurement.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. It is not medical advice. Fasoracetam is not FDA-approved for any indication and is sold as a research compound. Do not use alongside GABA-active substances (phenibut, baclofen, benzodiazepines) without understanding additive effects. Always consult a qualified healthcare provider before use.